PhaseBio Pharmaceuticals Research and Development Expense of Revenue

Research and Development Expense of Revenue of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending June 29, 2021 was 264.71% (a Infinity% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue increased by Infinity%
  • Annual Research and Development Expense of Revenue for 2020 was 22527.5% (a 268.92% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 6106.26% (a 116.33% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2018 was 2822.6% (a Infinity% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending June 29, 2021 was 767.12% (a Infinity% increase compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue increased by Infinity% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
767.12% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of PhaseBio Pharmaceuticals

Most recent Research and Development Expense of Revenueof PHAS including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 264.71% 0.0%
2020 0.0% 0.0% 0.0% 3577.81% 22527.5%
2019 1096.99% 3746.06% 1106.83% 876.11% 6106.26%
2018 2208.56% 1059.37% 0.0% 0.0% 2822.6%
2017 0.0% 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.